Dr Kirit Ardeshna

Ms Kirit ArdeshnaTel: 020 3447 9443
Fax: 0203 447 9870
Email: Harsharan.Chana@uclh.nhs.uk

Location:
University College Hospital

Specialities:
Hodgkin lymphoma, Non-Hodgkin lymphoma, Blood Diseases (clinical haematology)

Professional background

  • Medical School: Gonville and Caius College, Cambridge University and University College London 1984-1990
  • Haematology training: UCLH rotation including Great Ormond Street, Mount Vernon Cancer Centre
  • Doctorate of Medicine University of London (awarded 2001)
  • 2002 appointed Consultant haemato-oncologist at UCLH and Honorary Consultant at Mount Vernon Cancer Centre
  • 2006, Fellow of the Royal College of Physicians
  • 2008, Fellow of the Royal College of Pathologists

Research interests

Dr Kirit Ardeshna specialises in treating patients with haematological malignancies. He has a particular interest in non-Hodgkin's and Hodgkin's Lymphoma and is actively involved in clinical research. He is a member of the National Cancer Research Institute Lymphoma Study Group and is a committee member of the British Committee for Standards in Haematology.  He is a medical advisor to the Lymphoma Association. He is the Lead clinician for Haematology at UCLH. He sees patients privately as well as on the NHS.

Publications

Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH, Linch DC, Ardeshna KM. Br J Haematol. 2011 Jan;152(2):175-81
 
Facilities for the treatment of adults with haematological malignancies--'Levels of Care': BCSH Haemato-Oncology Task Force 2009. Matthey F, Parker A, Rule SA, Wimperis JZ, Ardeshna KM, Bird JM, Cullis J, Lyttelton MP, McMillan A, Jackson GH. Hematology. 2010 Apr;15(2):63-9
 
Treatment for lymph node tuberculosis must be preceded by adequate pathological investigation of the lymphadenopathy. RS Sellar, EL Corbett, SD’Sa, DC Linch, K M Ardeshna, British Medical Journal 2010;340:c63

Should we implement 'opt-out' HIV testing for patients with lymphoma? Cave J, Edwards SG, Miller RF, Ardeshna KM, Lee SM. Clin Med. 2009 Aug;9(4):320-2.

Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption.Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S. Br J Dermatol. 2009 Sep;161(3):717-9.

Follicular lymphoma involving the orbit. Yap YC, Ardeshna K, Kosmin A, Rose GE. Ann Ophthalmol (Skokie). 2007 39 p163-5

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value. Ardeshna KM. Core Evidence. 2007;2(2):121–129.

Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Br J Haem. 2005 Oct;131(2):193-200

Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first line salvage therapy regimens. Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D’Sa S, Mackinnon S, Hoskin PJ, Goldstone AH,  and  Linch DC. Brit J Haem 2005 130 p363-72

Watchful waiting in asymptomatic advanced stage low-grade NHL. Ardeshna KM. Current Medical Literature Leukaemia and Lymphoma. 2004 12 p25-29

Etoposide, methylprednisolone, cytarabine & cisplatin successfully cytoreduces resistant myeloma patients & mobilizes them for transplant without adverse effects. D'Sa S, Yong K, Kyriakou C, Bhattacharya S, Peggs KS, Foulkes B, Watts MJ, IngsSJ, Ardeshna KM,Goldstone AH,Williams CD. Brit J Haem. 2004 125 p756

Long-term effect of a watch & wait policy versus immediate systemic treatment for asymptomatic advanced stage NHL: a randomised controlled trial. KM Ardeshna, P Smith, A Norton, BW Hancock, PJ Hoskin, KA MacLennan, RE Marcus, A Jelliffe, G Vaughan Hudson and DC Linch The Lancet 2003 362 p516-22

GMC/GDC number: 3483949